NRG Therapeutics Ltd.

AktivBiotechStevenage, GBGegr. 2018Website

NRG Therapeutics Ltd. is an innovative biotechnology company based in Stevenage, UK, focusing on developing novel therapies for neurodegenerative diseases such as Parkinson's and ALS. Founded in 2018, the company researches oral, brain-penetrant small molecules targeting the mitochondrial permeability transition pore to restore mitochondrial function and reduce neuroinflammation, aiming to slow or stop disease progression. Its lead program, NRG5051, has shown promising neuroprotective properties preclinically and is expected to enter clinical trials in early 2026. It has secured significant funding including a £50 million Series B round in September 2025, with investors like Dementia Discovery Fund, M Ventures, Novartis Venture Fund, and British Business Bank.